GROWTH-HORMONE-RELEASING HORMONE ANALOG / ENDOCRINE RESEARCH
CJC-1295 is a synthetic growth-hormone-releasing hormone analog developed to extend biological activity through drug-affinity-complex technology. Published human research has examined its pharmacokinetics and effects on growth hormone and IGF-1 concentrations, but clinical outcome evidence remains limited.
PRIMARY RESEARCH AREAS
Growth-hormone-releasing hormone signaling; growth hormone secretion; IGF-1 response; pharmacokinetics; endocrine research
EVIDENCE LEVEL
Human pharmacokinetic and endocrine-response data exist; controlled clinical outcome evidence remains limited.
CJC-1295 was developed as a longer-acting growth-hormone-releasing hormone analog. Published research has primarily characterized hormone responses and pharmacokinetics rather than established clinical benefits.
Authentic CJC-1295 with drug-affinity-complex technology should not be treated as interchangeable with shorter-acting GHRH analogs commonly discussed as “CJC-1295 without DAC.”
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone, the hypothalamic signal that acts at the pituitary to promote growth hormone secretion. It was developed to address the short duration of native GHRH signaling.
Endogenous GHRH, shorter-acting GHRH analogs, and CJC-1295 with DAC are related but distinct molecular and pharmacokinetic entities. The commercial phrase “CJC-1295 without DAC” is often used for shorter-acting analogs, including modified GRF (1-29), but that naming can obscure important structural and exposure differences from CJC-1295 with DAC.
Evidence for one of these entities should therefore not be assumed to apply to another.
Scientific interest in CJC-1295 has centered on extending the duration of GHRH-mediated signaling. Drug-affinity-complex technology was developed to support prolonged circulating activity through albumin association.
This pharmacokinetic strategy is distinct from simply using a shorter GHRH analog. It provides research context, not evidence of broad clinical or performance outcomes.
At a high level, GHRH receptor activation in the pituitary can stimulate growth hormone secretion, which can subsequently influence circulating IGF-1. CJC-1295 was designed to extend exposure compared with native GHRH.
Mechanistic and biomarker effects provide information about endocrine signaling, but they do not by themselves establish clinically meaningful benefit.
Published human research has examined pharmacokinetics and endocrine-response measures in healthy adults. A randomized, placebo-controlled study reported sustained, dose-dependent increases in circulating GH and IGF-1 after CJC-1295 with DAC, alongside a multi-day estimated half-life.
A separate human study found increased trough and mean GH secretion and increased IGF-1 while GH pulsatility was preserved. These are demonstrated biomarker changes, not demonstrated clinical outcomes such as changes in body composition, recovery, or aging.
The original preclinical DAC research characterized CJC-1295 as an hGRF(1-29) analog engineered for extended activity through albumin binding. Evidence for shorter-acting GHRH analogs should not be substituted for evidence about CJC-1295 with DAC.
Limitations include small human study populations, limited controlled research using clinically meaningful endpoints, and uncertainty about long-term safety. Current research does not establish broad therapeutic or performance outcomes.
A further limitation is nomenclature: CJC-1295 with DAC and shorter-acting GHRH analogs commonly called “CJC-1295 without DAC” are not interchangeable, and commercial terminology can obscure that distinction.
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799–805. PMID: 16352683. DOI: 10.1210/jc.2005-1536.
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792–4797. PMID: 17018654. DOI: 10.1210/jc.2006-1702.
Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor hGRF(1-29)-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052–3058. PMID: 15817669. DOI: 10.1210/en.2004-1286.
Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone and IGF Research. 2009;19(6):471–477. PMID: 19386527. DOI: 10.1016/j.ghir.2009.03.001.
References were reviewed against primary-source or PubMed records. The profile distinguishes CJC-1295 with DAC from shorter-acting GHRH analogs throughout.
The direct literature includes preclinical pharmacology and small human endocrine studies. It is better suited to characterizing exposure and hormone biomarkers than to establishing clinical outcomes.
CELLULAR / IN-VITRO EVIDENCE
Mechanistic research establishes that CJC-1295 can act as a long-acting GHRH analog in experimental systems. It cannot establish long-term human outcomes or broad clinical efficacy.
ANIMAL / PRECLINICAL EVIDENCE
Preclinical work characterized albumin-binding CJC-1295 analogs and endocrine activity in rat systems. These findings support pharmacology research but should not be extrapolated directly to human clinical outcomes.
Human studies in healthy adults have documented pharmacokinetic properties and changes in GH and IGF-1 biomarkers. Those measurements do not establish clinically meaningful benefit, and controlled outcome research remains limited.
Reasonably established within published research: CJC-1295 with DAC is a longer-acting GHRH analog, and human studies have reported sustained changes in GH and IGF-1 biomarkers.
Unestablished: broad therapeutic, performance, body-composition, recovery, or anti-aging outcomes; a comprehensive long-term safety profile; and equivalence between CJC-1295 with DAC and shorter-acting analogs.
Published human studies reported no serious adverse reactions in their limited study settings. Their size and duration do not establish a comprehensive long-term safety or tolerability profile.
Priorities include larger controlled human studies, clinically meaningful endpoints, long-term safety follow-up, standardized compound characterization, and clearer nomenclature distinguishing CJC-1295 with DAC from shorter-acting GHRH analogs.
Interpretation should remain anchored to the precise compound and study endpoint rather than treating biomarker changes as proof of clinical benefit.
EDITORIALLY REVIEWED
LAST REVIEWED
Research profile reviewed for source accuracy, evidence classification, and distinction between CJC-1295 with DAC and shorter-acting GHRH analogs commonly described as “CJC-1295 without DAC.”